Bleomycin electrosclerotherapy (BEST) for the treatment of vascular malformations. An International Network for Sharing Practices on Electrochemotherapy (InspECT) study group report.
bleomycin
bleomycin electrosclerotherapy
electrochemotherapy
vascular malformations
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
received:
26
05
2023
accepted:
03
06
2023
medline:
22
6
2023
pubmed:
21
6
2023
entrez:
21
6
2023
Statut:
epublish
Résumé
Biomedical applications of electroporation are expanding out of the field of oncology into vaccination, treatment of arrhythmias and now in the treatment of vascular malformations. Bleomycin is a widely used sclerosing agent in the treatment of various vascular malformations. The application of electric pulses in addition to bleomycin enhances the effectiveness of the drug, as demonstrated by electrochemotherapy, which utilizes bleomycin in the treatment of tumors. The same principle is used in bleomycin electrosclerotherapy (BEST). The approach seems to be effective in the treatment of low-flow (venous and lymphatic) and, potentially, even high-flow (arteriovenous) malformations. Although there are only a few published reports to date, the surgical community is interested, and an increasing number of centers are applying BEST in the treatment of vascular malformations. Within the International Network for Sharing Practices on Electrochemotherapy (InspECT) consortium, a dedicated working group has been constituted to develop standard operating procedures for BEST and foster clinical trials. By treatment standardization and successful completion of clinical trials demonstrating the effectiveness and safety of the approach, higher quality data and better clinical outcomes may be achieved.
Sections du résumé
BACKGROUND
Biomedical applications of electroporation are expanding out of the field of oncology into vaccination, treatment of arrhythmias and now in the treatment of vascular malformations. Bleomycin is a widely used sclerosing agent in the treatment of various vascular malformations. The application of electric pulses in addition to bleomycin enhances the effectiveness of the drug, as demonstrated by electrochemotherapy, which utilizes bleomycin in the treatment of tumors. The same principle is used in bleomycin electrosclerotherapy (BEST). The approach seems to be effective in the treatment of low-flow (venous and lymphatic) and, potentially, even high-flow (arteriovenous) malformations. Although there are only a few published reports to date, the surgical community is interested, and an increasing number of centers are applying BEST in the treatment of vascular malformations. Within the International Network for Sharing Practices on Electrochemotherapy (InspECT) consortium, a dedicated working group has been constituted to develop standard operating procedures for BEST and foster clinical trials.
CONCLUSIONS
By treatment standardization and successful completion of clinical trials demonstrating the effectiveness and safety of the approach, higher quality data and better clinical outcomes may be achieved.
Identifiants
pubmed: 37341196
pii: raon-2023-0029
doi: 10.2478/raon-2023-0029
pmc: PMC10286891
doi:
Substances chimiques
Bleomycin
11056-06-7
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
141-149Informations de copyright
© 2023 Tobian Muir et al., published by Sciendo.
Références
Mol Ther. 2022 Jan 5;30(1):311-326
pubmed: 34547465
PLoS One. 2013;8(3):e59557
pubmed: 23555705
J Control Release. 2021 Apr 10;332:623-635
pubmed: 33705828
Acta Oncol. 2018 Jul;57(7):874-882
pubmed: 29577784
Eur J Cancer. 1999 Apr;35(4):672-7
pubmed: 10492645
Front Oncol. 2022 Nov 29;12:1025270
pubmed: 36523962
Int J Surg. 2019 Dec;72:34-42
pubmed: 31618680
Expert Rev Anticancer Ther. 2010 May;10(5):729-46
pubmed: 20470005
J Vasc Surg Venous Lymphat Disord. 2021 May;9(3):731-739
pubmed: 33045393
J Control Release. 2018 Apr 28;276:30-41
pubmed: 29476881
Eur J Surg Oncol. 2021 Aug;47(8):1836-1846
pubmed: 33726951
Eur J Surg Oncol. 2019 Feb;45(2):92-102
pubmed: 30528893
J Cutan Med Surg. 2020 Mar/Apr;24(2):218-219
pubmed: 32208013
Dermatol Surg. 2020 Apr;46(4):491-498
pubmed: 31574025
Genes Dis. 2018 May 17;5(3):194-203
pubmed: 30320184
Eur J Surg Oncol. 2018 May;44(5):651-657
pubmed: 29402556
Neurointervention. 2020 Mar;15(1):4-17
pubmed: 31940716
Radiol Oncol. 2022 Aug 14;56(3):398-408
pubmed: 35535423
Vaccines (Basel). 2023 Apr 30;11(5):
pubmed: 37243029
Biochim Biophys Acta. 2002 Jan 15;1569(1-3):51-8
pubmed: 11853957
Dermatol Surg. 2022 Jan 1;48(1):67-71
pubmed: 34608081
Front Oncol. 2022 Nov 18;12:1011721
pubmed: 36465339
Eur J Cancer. 2020 Oct;138:30-40
pubmed: 32836172
Tech Vasc Interv Radiol. 2018 Jun;21(2):45-54
pubmed: 29784122
Cancer Immunol Immunother. 2015 Oct;64(10):1315-27
pubmed: 26067277
Radiol Oncol. 2020 Jul 29;54(3):317-328
pubmed: 32726295
Br J Cancer. 2008 Jan 29;98(2):388-98
pubmed: 18182988
Tech Vasc Interv Radiol. 2019 Dec;22(4):100635
pubmed: 31864534
Annu Rev Biomed Eng. 2014 Jul 11;16:295-320
pubmed: 24905876
Eur J Radiol Open. 2017 May 14;4:63-68
pubmed: 28540347
Pediatrics. 2020 Dec;146(6):
pubmed: 33234668
J Plast Reconstr Aesthet Surg. 2016 Mar;69(3):295-304
pubmed: 26723834
Cancers (Basel). 2020 Dec 15;12(12):
pubmed: 33333941
Front Cell Dev Biol. 2023 Apr 28;11:1146195
pubmed: 37187618
Basic Clin Pharmacol Toxicol. 2018 Sep;123(3):247-256
pubmed: 29573558
Neuroimaging Clin N Am. 2009 May;19(2):219-40, Table of Contents
pubmed: 19442907
Eur J Surg Oncol. 2020 Sep;46(9):1628-1633
pubmed: 32387070
J Surg Oncol. 2016 Aug;114(2):246-53
pubmed: 27156580
Br J Oral Maxillofac Surg. 2017 Nov;55(9):977-979
pubmed: 29055573
Clin Case Rep. 2018 Sep 04;6(10):2011-2014
pubmed: 30349718
Int J Dermatol. 2023 Jan;62(1):115-119
pubmed: 35556245
Eur J Cancer. 1991;27(1):68-72
pubmed: 1707289
PLoS One. 2017 Jul 7;12(7):e0180709
pubmed: 28686650
Cancers (Basel). 2023 Mar 04;15(5):
pubmed: 36900388
Cancers (Basel). 2021 Aug 25;13(17):
pubmed: 34503099
Am J Physiol Heart Circ Physiol. 2023 Jan 1;324(1):H109-H121
pubmed: 36459445